All articles tagged with #obesity drugs
Originally Published 2 days ago — by CNBC
The upcoming JPMorgan Healthcare Conference will showcase industry updates on drug pipelines, M&A activity, and the impact of recent drug pricing deals, with a focus on managing patent expirations, obesity treatments, and potential new drug developments from major pharma companies like Bristol Myers Squibb, Merck, Novo Nordisk, and Eli Lilly.
Originally Published 2 days ago — by CNBC
Amazon Pharmacy now offers Novo Nordisk's Wegovy weight loss pill, including an oral version with competitive pricing, expanding access to obesity treatments beyond traditional channels and reaching new patients through online and physical pharmacy outlets.
Originally Published 1 month ago — by Nature
Research suggests that blockbuster obesity drugs like semaglutide may have potential in treating addiction by acting on brain pathways related to reward and craving, with ongoing clinical trials exploring their efficacy for alcohol, nicotine, and opioid dependence, potentially revolutionizing addiction medicine.
Originally Published 2 months ago — by statnews.com
Pfizer's $10 billion acquisition of Metsera, a company developing experimental weight loss drugs, highlights significant activity in biotech mergers and investments, with venture funds like Population Health Partners and ARCH Venture Partners poised to profit greatly. The deal underscores both opportunities and cautionary lessons in biotech M&A and investment strategies.
Originally Published 2 months ago — by statnews.com
Pfizer has acquired Metsera for up to $10 billion in a high-stakes deal to enter the obesity treatment market, aiming to recover from past struggles in this sector and boost its declining COVID-19 vaccine sales. The success of the investment remains uncertain, with Pfizer CEO Albert Bourla acknowledging the risk of overpaying if the venture fails or gaining a significant advantage if it succeeds.
Originally Published 2 months ago — by Barron's
Eli Lilly's stock reached a new high after a positive analyst upgrade and a deal with the U.S. government to lower drug prices, which is expected to boost obesity drug adoption and future drug launches, despite some concerns over valuation and competition.
Originally Published 2 months ago — by TipRanks
Eli Lilly's stock (LLY) was upgraded following news that obesity drugs will now be covered by Medicare, potentially boosting the company's prospects in the pharmaceutical industry.
Originally Published 2 months ago — by AP News
Pfizer has won the bid to acquire Metsera, a development-stage obesity drug company, surpassing Novo Nordisk in a competitive deal valued at up to $86.25 per share, as both companies vie to expand their presence in the obesity and diabetes treatment markets.
Originally Published 2 months ago — by Bloomberg.com
Novo Nordisk's CEO Mike Doustdar withdrew from a $10 billion bid for Metsera after Pfizer matched its offer, highlighting intense competition in the obesity drug market. Despite setbacks, Novo plans to pursue other acquisitions and focus on its pipeline, including new treatments and potential breakthroughs like a pill form of semaglutide. The company is shifting towards a more aggressive, market-driven approach to regain its leadership in the booming weight-loss industry.
Originally Published 2 months ago — by Bloomberg.com
Pfizer agreed to acquire Metsera for $10 billion after a bidding war with Novo Nordisk, with Pfizer securing US regulatory approval and offering a higher bid, aiming to strengthen its position in the growing obesity drug market.
Originally Published 2 months ago — by Reuters
Pfizer has accepted a $10 billion bid to acquire Metsera, potentially ending a bidding war with Novo Nordisk over obesity drug assets, with the deal expected to close after Metsera's November 13 shareholder meeting.
Originally Published 2 months ago — by CNBC
Pfizer has agreed to acquire Metsera for $10 billion, ending a bidding war with Novo Nordisk over a promising obesity drug portfolio, with Pfizer offering a premium price and contingent payments, while Metsera's board recommends shareholders accept the deal amid ongoing market competition.
Originally Published 2 months ago — by CNBC
Tesla shareholders approved Elon Musk's nearly $1 trillion pay plan, linked to milestones like humanoid robot delivery; AI stocks face sell-off fears amid valuation concerns; Trump announces drug price cuts and Medicare coverage for obesity medications; U.S. officials clarify no federal bailout for AI, despite industry growth forecasts; Target plans to improve in-store experience by limiting online order fulfillment in stores.
Originally Published 2 months ago — by Bloomberg.com
Eli Lilly and Novo Nordisk have reached deals with the Trump administration to lower prices for their weight-loss drugs like Zepbound and Wegovy, making them more accessible to Medicare patients and receiving tariff relief, with the aim of expanding access and reducing costs for millions of Americans.
Originally Published 2 months ago — by NPR
The Trump administration announced deals with Novo Nordisk and Eli Lilly to lower the cost of obesity and Type 2 diabetes drugs for Medicare beneficiaries to $50 copays, aiming to improve access and reduce overall healthcare spending through broader drug pricing reforms.